Epoetin alfa is a lab-made (recombinant) copy of erythropoietin (EPO), the kidney hormone that tells the bone marrow to make red blood cells. It was first approved in the US in 1989 and is sold as Epogen, Procrit and the biosimilar Retacrit. Doctors use it to treat anemia from chronic kidney disease, some cancer chemotherapy and the HIV drug zidovudine, and to reduce transfusions around certain surgeries (Epogen label).
The most important fact is its boxed warning. In controlled trials, using EPO-type drugs to push hemoglobin above 11 g/dL raised the risk of death, heart attack, stroke and blood clots, and in several cancers it shortened survival or sped tumor growth. Outside medicine, EPO is the classic endurance-doping drug. It is banned at all times by the World Anti-Doping Agency (WADA), and anti-doping labs can detect it.
This page summarizes what the FDA labels, clinical trials and anti-doping research report. It is for education only and is not medical advice.
| Property | Detail |
|---|---|
| Drug class | Erythropoiesis-stimulating agent (ESA); recombinant glycoprotein hormone |
| US brands | Epogen (Amgen), Procrit (Janssen; made by Amgen), Retacrit (epoetin alfa-epbx, Pfizer biosimilar) |
| First US approval | 1989 (Epogen/Procrit); 2018 (Retacrit) |
| Route | Intravenous (IV) or subcutaneous (SC) injection |
| Epogen strengths | 2,000–10,000 Units/mL single-dose vials; 20,000 Units multiple-dose vials with benzyl alcohol |
| Labeled starting doses | CKD: 50–100 Units/kg 3 times weekly; chemotherapy: 150 Units/kg 3 times weekly or 40,000 Units weekly |
| Half-life (label) | 4–13 h after IV dosing in CKD; about 40 h (range 16–67 h) after SC dosing in cancer patients |
| Boxed warning | Death, heart attack, stroke, venous thromboembolism, vascular access clotting, tumor progression |
| US status | Prescription-only biologic; not listed in Schedule III (21 CFR 1308.13) |
| WADA | Prohibited at all times, class S2.1.1 (non-specified) |
What it is
Natural EPO is a glycoprotein: a 165-amino-acid protein chain with sugar chains (glycans) attached, weighing about 30.4 kDa. The kidneys are its main source. Its production is switched on by hypoxia-inducible factors (HIFs), proteins that rise when tissue oxygen falls. EPO keeps red cell precursors in the marrow alive and multiplying. A lack of EPO is the main cause of anemia in chronic kidney disease (CKD) (Jelkmann, Transfus Med Hemother 2013).
The human EPO gene was cloned in 1985. When inserted into Chinese hamster ovary cells, it produced EPO that was biologically active (Lin et al., PNAS 1985). The first trial gave the recombinant hormone IV three times weekly to 25 anemic hemodialysis patients. Of 18 who received effective doses, 12 stopped needing transfusions, and blood pressure rose in four (Eschbach et al., NEJM 1987).
Epoetin alfa has the same amino acid sequence as natural EPO and works by the same mechanism. The label describes it as a 165-amino-acid glycoprotein of about 30,400 daltons made in mammalian cells (Epogen label). The three US products differ mainly in maker and formulation:
| Product | Nonproprietary name | Maker | Notes |
|---|---|---|---|
| Epogen | epoetin alfa | Amgen | Reference product; contains human albumin |
| Procrit | epoetin alfa | Janssen (manufactured by Amgen) | Same active drug as Epogen |
| Retacrit | epoetin alfa-epbx | Pfizer (Hospira) | Biosimilar to Epogen/Procrit, approved 2018 |
Sources: Epogen label; Procrit label; Retacrit label.
A “biosimilar” is a biologic approved because it is highly similar to an existing product with no clinically meaningful differences, as the Retacrit label explains. Johnson & Johnson’s epoetin alfa brand is Eprex (Schellekens & Jiskoot, J Immunotoxicol 2006).
Long-acting relatives
Two later ESAs were engineered to last longer in the blood. They are mentioned here only for context:
- Darbepoetin alfa (Aranesp, US approval 2001) carries 5 sugar chains instead of 3. Its IV terminal half-life is about 21 h, roughly three times that of epoetin alfa (Aranesp label).
- Methoxy polyethylene glycol-epoetin beta (Mircera, often called CERA; US approval 2007) has a PEG chain of about 30,000 daltons attached. Its terminal half-life was about 119 h after IV and 124 h after SC dosing in peritoneal dialysis patients (Mircera label).
Both labels carry the same ESA boxed warning, and both drugs are named on the WADA list.
How it works in the body
Epoetin alfa raises the reticulocyte count (young red cells) within 10 days. Red cell count, hemoglobin and hematocrit (the share of blood made up of red cells) rise after that, usually within 2–6 weeks. The size of the rise depends on dose (Epogen label).
| Measure (label) | Value |
|---|---|
| IV half-life, CKD patients | 4–13 h |
| Time to peak after SC dose | 5–24 h |
| SC half-life, anemic cancer patients | About 40 h (range 16–67 h) |
| 40,000 Units weekly vs 150 Units/kg 3 times weekly | 3–7× higher peak, 2–3× higher AUC, 50% lower clearance |
| Accumulation over 4–6 weeks | None seen with either regimen |
In hemodialysis patients, the label reports a dose-dependent hemoglobin rise over 2 weeks at IV starting doses given 3 times weekly:
| Starting dose (3× weekly IV) | Hemoglobin rise in 2 weeks |
|---|---|
| 50 Units/kg | 0.5 g/dL |
| 100 Units/kg | 0.8 g/dL |
| 150 Units/kg | 1.2 g/dL |
The label adds that no greater response is seen above 300 Units/kg 3 times weekly in these patients. Most patients with CKD need iron supplements during therapy, and the label advises iron when ferritin is under 100 mcg/L or transferrin saturation is under 20%.
Hemoglobin concentration also rises for a second reason. In 8 healthy volunteers given EPO for 15 weeks to hold hematocrit near 50%, red cell volume rose (from 2,933 to 3,210 mL at week 5), while plasma volume fell (from 3,645 to 3,267 mL). The authors estimated that the plasma-volume drop accounted for 38–54% of the gain in arterial oxygen content (Lundby et al., J Physiol 2007).
Approved medical use
The Epogen label lists these indications (Epogen label):
| Indication | Labeled adult starting dose | Key conditions |
|---|---|---|
| Anemia of CKD (on or not on dialysis) | 50–100 Units/kg 3 times weekly, IV or SC | Start when hemoglobin is under 10 g/dL; reduce or stop as it nears 11 g/dL on dialysis |
| Anemia from zidovudine in HIV | 100 Units/kg 3 times weekly | Zidovudine ≤ 4,200 mg/week and serum EPO ≤ 500 mUnits/mL |
| Anemia from myelosuppressive chemotherapy | 150 Units/kg SC 3 times weekly or 40,000 Units SC weekly | Hemoglobin under 10 g/dL and at least 2 more months of planned chemotherapy; stop when the course ends |
| Fewer transfusions in elective noncardiac, nonvascular surgery | 300 Units/kg daily for 15 days, or 600 Units/kg weekly × 4 doses | Hemoglobin over 10 to ≤ 13 g/dL; DVT prophylaxis recommended |
The label also lists limits of use. Epoetin alfa has not been shown to improve quality of life, fatigue or well-being. It is not indicated when cancer chemotherapy is expected to cure, for cancer patients on hormonal, biologic or radiation therapy alone, for cardiac or vascular surgery, or as a substitute for transfusion when anemia must be corrected immediately.
For CKD, the label says to increase the dose no more often than every 4 weeks, cut it by 25% or more if hemoglobin rises over 1 g/dL in any 2-week period, and notes that raising the dose further after a 12-week escalation period is unlikely to help and may increase risk.
What the research shows
Anemia of kidney disease
In 13 studies of 1,010 dialysis patients given IV epoetin alfa, more than 90% had improved hemoglobin, and in the three largest studies more than 95% avoided transfusions. In a 26-week double-blind trial of 118 dialysis patients starting at about 7 g/dL, hemoglobin rose to about 11 g/dL on epoetin alfa and did not change on placebo. Exercise tolerance and self-reported physical function also improved (Epogen label).
Higher hemoglobin targets cause harm
Three large randomized trials tested whether aiming for near-normal hemoglobin in CKD would help the heart or kidneys. All three found worse cardiovascular outcomes in the higher-target group and no slowing of kidney failure (Epogen label):
| Trial (n) | Population | Hemoglobin target, high vs low | Main adverse finding, high target |
|---|---|---|---|
| Normal Hematocrit Study (1,265) | Hemodialysis with heart failure or coronary disease | 14 vs 10 g/dL | All-cause mortality HR 1.27 (95% CI 1.04–1.54); 35% vs 29% died |
| CHOIR (1,432) | CKD not on dialysis | 13.5 vs 11.3 g/dL | Major cardiovascular events 18% vs 14%, HR 1.34 (95% CI 1.03–1.74) |
| TREAT (4,038), darbepoetin | CKD with type 2 diabetes, not on dialysis | 13 vs placebo (rescue under 9 g/dL) | Stroke 2.1% vs 1.1% per year, HR 1.92 (95% CI 1.38–2.68) |
The label states that no trial has found a hemoglobin target, dose or dosing strategy that avoids these risks.
Cancer patients
ESAs reduce transfusions in chemotherapy-related anemia, but trials showed shorter survival or faster tumor growth. In one placebo-controlled trial of 939 women with metastatic breast cancer, 12-month survival was 70% on epoetin alfa vs 76% on placebo (HR 1.37, 95% CI 1.07–1.75), and the trial was stopped early (Epogen label).
A meta-analysis pooled individual data from 53 trials and 13,933 cancer patients given epoetin alfa, epoetin beta or darbepoetin. ESAs increased mortality during the active study period (combined HR 1.17, 95% CI 1.06–1.30) and worsened overall survival (HR 1.06, 95% CI 1.00–1.12) (Bohlius et al., Lancet 2009).
Endurance performance in healthy athletes
In controlled trials in healthy men, EPO raised hematocrit and laboratory measures of aerobic capacity. Whether that translates into faster real-world racing is less clear.
| Study | Design and n | Regimen | Main results |
|---|---|---|---|
| Birkeland et al., MSSE 2000 | Double-blind RCT, 20 male athletes | 5,000 Units 3 times weekly for 4 weeks | Hematocrit 42.7% to 50.8%; VO2max +7% (63.6 to 68.1 mL/kg/min) |
| Heuberger et al., Lancet Haematol 2017 | Double-blind RCT, 48 trained amateur cyclists | Epoetin beta, mean 6,000 IU/week SC for 8 weeks | VO2max 60.1 vs 57.4 mL/kg/min; max power 351.6 vs 341.2 W; no difference in 45-min submaximal test or Mont Ventoux race time |
VO2max is the maximal rate at which the body can use oxygen. Note that the Heuberger trial used epoetin beta, a closely related recombinant EPO, not epoetin alfa.
“EPO adds a fixed amount to race performance.” The evidence is mixed. Lab tests of maximal effort improve, but in the only placebo-controlled trial with a road race, race times did not differ (1 h 40 min 32 s vs 1 h 40 min 15 s). That trial enrolled non-professional cyclists and tested one climb, so it does not rule out effects in elite racing (Heuberger et al., Lancet Haematol 2017).
Side effects and risks
Boxed warning
The Epogen, Procrit and Retacrit labels carry this boxed warning, which is shared by the other ESAs (Epogen label):
- CKD: targeting hemoglobin over 11 g/dL raised the risk of death, serious cardiovascular events and stroke. Use the lowest dose that reduces transfusions.
- Cancer: ESAs shortened overall survival and/or increased tumor progression or recurrence in breast, non-small cell lung, head and neck, lymphoid and cervical cancers. Use only for anemia from myelosuppressive chemotherapy and stop when the course ends.
- Surgery: deep vein thrombosis (DVT) prophylaxis is recommended because of a higher DVT risk.
In a trial of 680 spinal surgery patients not on anticoagulants, DVT occurred in 4.7% on epoetin alfa vs 2.1% with standard care alone. In a coronary bypass surgery trial, 7 of 126 patients on Epogen died vs none of 56 on placebo.
Common adverse reactions
In placebo-controlled trials in dialysis patients, these occurred more often on epoetin alfa (Epogen label):
| Adverse reaction | Epogen (n = 148) | Placebo (n = 96) |
|---|---|---|
| Hypertension | 27.7% | 12.5% |
| Arthralgia (joint pain) | 16.2% | 3.1% |
| Pyrexia (fever) | 10.1% | 8.3% |
| Dizziness | 9.5% | 8.3% |
| Dialysis circuit clotting | 8.1% | 4.2% |
| Vascular access thrombosis | 8.1% | 2.1% |
Blood pressure and seizures
About 25% of dialysis patients needed new or increased blood pressure medicine after starting epoetin alfa. Hypertensive encephalopathy and seizures have been reported, and the label states that the drug increases seizure risk in CKD. Uncontrolled hypertension is a contraindication.
Pure red cell aplasia
Rarely, patients develop antibodies that neutralize both the drug and their own EPO. This causes pure red cell aplasia (PRCA), a severe anemia in which the marrow stops making red cells. A case series described 13 such patients with chronic renal failure (Casadevall et al., NEJM 2002). Many cases were linked to Eprex after a 1998 formulation change that replaced human albumin with polysorbate 80 (Schellekens & Jiskoot, J Immunotoxicol 2006). The US label says to stop permanently and not switch to another ESA if PRCA develops.
Other warnings and contraindications
The label also lists:
- serious allergic reactions, including anaphylaxis and angioedema;
- severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis;
- loss of response, which calls for a search for causes such as iron deficiency, infection, inflammation or bleeding;
- benzyl alcohol in multiple-dose vials, which is contraindicated in neonates, infants, and pregnant or breastfeeding women (“gasping syndrome” in infants);
- a need for more heparin during hemodialysis to keep the circuit from clotting.
Risks of non-medical use
There are no controlled long-term safety data for EPO misuse in healthy athletes. In the 8-week cyclist trial, adverse events were mild (grade 1–2) and similar to placebo (Heuberger et al., Lancet Haematol 2017), but that trial was small and closely monitored. The clinical signals above (high hemoglobin targets, clotting, raised blood pressure) are the main documented concerns, and reviews describe the health risks of ESA misuse as potentially irreversible (Salamin et al., Mol Cell Endocrinol 2018).
Monitoring
The label sets these checkpoints:
| What | When |
|---|---|
| Iron status (ferritin, transferrin saturation) | Before and during treatment |
| Hemoglobin | At least weekly after starting or changing dose until stable, then at least monthly (CKD) |
| Blood pressure control | Before and during treatment |
| Neurologic symptoms | Closely during the first several months (CKD) |
| Anti-EPO antibodies | If severe anemia with a low reticulocyte count develops |
Doping and detection
WADA status
The WADA 2026 Prohibited List bans erythropoietins at all times, in and out of competition, under S2.1.1 (erythropoietin receptor agonists). The same class names darbepoetins, EPO-Fc, CERA and EPO-mimetic peptides. All S2 substances are non-specified. Related classes include HIF-activating drugs such as roxadustat and daprodustat (S2.1.2), and method M1 bans blood transfusions and other blood manipulation.
Direct detection
In 2000, the French national anti-doping lab published a urine test that separates recombinant from natural EPO by isoelectric focusing, which sorts protein variants by electric charge (Lasne & de Ceaurriz, Nature 2000). Natural urinary EPO is present at only about 1 IU/L and shows more than 10 charge variants, and the pattern changes clearly after recombinant hormone is given (Lasne et al., Anal Biochem 2002). Gel electrophoresis methods (SAR-PAGE and SDS-PAGE) are now also used (Martin et al., Drug Test Anal 2021).
Because the IV half-life is only hours, the window for direct detection is short (Dehnes et al., Drug Test Anal 2013). In a study of small repeated “microdoses,” improved methods detected EPO in blood and urine 24–72 h after a dose. Urine SDS-PAGE identified 100% of samples at 48 h and 91% at 72 h (Martin et al., Drug Test Anal 2021).
Indirect detection
Since December 2009, WADA has applied Athlete Biological Passport guidelines. The passport tracks an athlete’s red cell and reticulocyte markers over time and flags changes that are not physiologic. This allows cases to be built even when the drug itself is no longer detectable (Jelkmann & Lundby, Blood 2011). In an early trial, a blood marker of red cell production (soluble transferrin receptor) stayed raised for only about 1 week after EPO, while the gain in VO2max lasted longer (Birkeland et al., MSSE 2000).
Key takeaways
- A copy of a natural hormone. Epoetin alfa has the same amino acid sequence as human EPO and raises red cell production, with hemoglobin rising over 2–6 weeks.
- Approved for specific anemias. Labeled uses are anemia from CKD, zidovudine and myelosuppressive chemotherapy, and reducing transfusions in certain elective surgery.
- More is not better. Trials targeting hemoglobin of 13–14 g/dL raised death, heart attack, stroke and clotting risk, and ESAs shortened survival in several cancers.
- Lab gains, uncertain race gains. In healthy men, EPO raised hematocrit and VO2max, but the one placebo-controlled road-race trial found no difference in race time.
- Banned and detectable. WADA prohibits EPO and its long-acting relatives at all times; urine and blood tests detect recent use, and the Athlete Biological Passport tracks its effects over time.
Sources
- Amgen. Epogen (epoetin alfa) injection, prescribing information. DailyMed.
- Janssen Products. Procrit (epoetin alfa) injection, prescribing information. DailyMed.
- Pfizer. Retacrit (epoetin alfa-epbx) injection, prescribing information. DailyMed.
- Amgen. Aranesp (darbepoetin alfa) injection, prescribing information. DailyMed.
- Vifor (International). Mircera (methoxy polyethylene glycol-epoetin beta) injection, prescribing information. DailyMed.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA 2026 Prohibited List.
- Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 2013;40(5):302–309. PubMed.
- Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A. 1985;82(22):7580–7584. PubMed.
- Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73–78. PubMed.
- Lundby C, Thomsen JJ, Boushel R, et al. Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol. 2007;578(Pt 1):309–314. PubMed.
- Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373(9674):1532–1542. PubMed.
- Birkeland KI, Stray-Gundersen J, Hemmersbach P, et al. Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med Sci Sports Exerc. 2000;32(7):1238–1243. PubMed.
- Heuberger JAAC, Rotmans JI, Gal P, et al. Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trial. Lancet Haematol. 2017;4(8):e374–e386. PubMed.
- Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469–475. PubMed.
- Schellekens H, Jiskoot W. Erythropoietin-associated PRCA: still an unsolved mystery. J Immunotoxicol. 2006;3(3):123–130. PubMed.
- Salamin O, Kuuranne T, Saugy M, et al. Erythropoietin as a performance-enhancing drug: its mechanistic basis, detection, and potential adverse effects. Mol Cell Endocrinol. 2018;464:75–87. PubMed.
- Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature. 2000;405(6787):635. PubMed.
- Lasne F, Martin L, Crepin N, et al. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem. 2002;311(2):119–126. PubMed.
- Dehnes Y, Shalina A, Myrvold L. Detection of recombinant EPO in blood and urine samples with EPO WGA MAIIA, IEF and SAR-PAGE after microdose injections. Drug Test Anal. 2013;5(11-12):861–869. PubMed.
- Martin L, Martin JA, Collot D, et al. Improved detection methods significantly increase the detection window for EPO microdoses. Drug Test Anal. 2021;13(1):101–112. PubMed.
- Jelkmann W, Lundby C. Blood doping and its detection. Blood. 2011;118(9):2395–2404. PubMed.
- US Code of Federal Regulations. 21 CFR 1308.13, Schedule III. eCFR.